I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026, the actual value is USD 2.037 M.
EPS: As of FY2026, the actual value is USD -2.58.
EBIT: As of FY2026, the actual value is USD -8.367 M.
Segment Revenue
- Total Revenue: Total revenue was $2,036,651 for the year ended January 31, 2026, a decrease from $2,139,537 in the prior year ended January 31, 2025.
- Pocono Pharmaceuticals Segment Revenue: This segment generated $2,036,651 in 2026 and $2,139,537 in 2025, with revenue remaining relatively constant year-over-year.
- 4P Therapeutics Segment Revenue: This segment generated no revenue from contract research and development services in both 2026 and 2025.
- Revenue Category: All revenue for both years was categorized as “Sale of goods,” with no revenue from “Services.”
- Geographic Revenue: United States revenue was $2,029,021 in 2026 and $2,139,537 in 2025, while foreign revenue was $7,630 in 2026 and $0 in 2025.
Operational Metrics
- Gross Profit: Total gross profit was $566,308 for the year ended January 31, 2026, down from $743,317 in the prior year, primarily due to lower margins on tape sales.
- Pocono Pharmaceuticals Segment Gross Profit: This segment generated gross profits of $566,308 in 2026 and $743,317 in 2025.
- 4P Therapeutics Segment Gross Profit: This segment generated $0 in gross profit for both 2026 and 2025.
- Operating Expenses:
- Selling, General and Administrative (SG&A) Expenses: Increased to $6,993,140 in 2026 from $4,313,810 in 2025, mainly due to an increase in equity-based expenses.
- Research and Development (R&D) Expenses: Decreased to $1,891,129 in 2026 from $3,119,134 in 2025, mainly due to a reduction in labor costs.
- Goodwill and Intangibles Impairment Charge: The company incurred no charge in 2026, compared to $3,595,216 in 2025.
- Total Costs and Expenses: Were $10,354,612 in 2026, down from $12,424,380 in 2025.
- Loss from Operations: Was - $8,317,961 for the year ended January 31, 2026, an improvement from - $10,284,843 in the prior year.
- Other Income (Expense):
- Other Income: Was $110,864 in 2026, a decrease from $191,669 in 2025.
- Loss on Extinguishment of Debt: The company recorded no loss in 2026, compared to - $368,036 in 2025.
- Interest Expense: Was $22,535 in 2026, slightly up from $21,407 in 2025.
- Net Loss: The net loss was - $8,229,632 for the year ended January 31, 2026, an improvement compared to a net loss of - $10,482,617 for the year ended January 31, 2025.
- Net Loss Available to Common Shareholders: After a preferred stock dividend of - $21,814,166, the net loss available to common shareholders was - $30,043,798 or - $2.58 per share (basic and diluted) in 2026, compared to - $10,482,617 or - $0.99 per share (basic and diluted) in 2025.
Cash Flow
- Operating Cash Flow: Net cash used in operating activities was - $5,134,630 for the year ended January 31, 2026, compared to - $4,626,564 for the year ended January 31, 2025. Principal adjustments in 2026 included depreciation and amortization of $193,797 and stock-based compensation of $2,633,996.
- Free Cash Flow: The report does not explicitly present Free Cash Flow as a distinct metric.
Unique Metrics
- Research and Development Spending for Aversa Fentanyl: The company incurred $1,891,129 in R&D expenses for its Aversa Fentanyl product in 2026, compared to $3,119,134 in 2025. As of January 31, 2026, $4.7 million had been incurred under the agreement with Kindeva Drug Delivery, with an estimated $2.5 million required to complete development through NDA submission for the current workplan. An additional $3.0 million milestone payment is due to Kindeva upon FDA approval.
Outlook / Guidance
Management believes that sufficient funds will be generated from operations to fund operations for one year from the filing date, indicating improved operations and ability to continue as a going concern. The company plans to continue relying on sales of securities and debt issuance to support operations and fund the development of Aversa products, with an estimated $13 million required for Aversa Fentanyl R&D for FDA approval. The company intends to seek a small business waiver for the $4,682,003 standard NDA application fee for its first product in fiscal year 2026, with an annual program fee of $442,213 per prescription drug product after approval.